{"entity":{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","aka":[],"tldr":"Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant.","summary":"Graham Jackson was chief investigator of Myeloma XI, the largest myeloma trial ever run, which showed lenalidomide maintenance improves progression-free and overall survival in transplant-eligible patients and defined the benefit of triplet induction, and of the earlier Myeloma IX trial. He chairs the UK Myeloma Research Alliance and leads the RADAR trial of MRD-guided treatment.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jackson%20GH%5BAuthor%5D%20myeloma%20XI"}],"tags":["myeloma","maintenance","uk"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["newcastle-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Clinical Haematology, Newcastle University; Consultant, Freeman Hospital","institutionId":"newcastle-cancer-centre","specialisms":["Multiple myeloma","Maintenance therapy","Large pragmatic trials","Transplantation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jackson%20GH%5BAuthor%5D%20myeloma%20XI"}],"papers":[{"title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(18)30687-9"},{"title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX)","journal":"Lancet","year":2010,"doi":"10.1016/S0140-6736(10)62051-X"}],"orcid":"0000-0003-0756-969X"},"route":"/people/graham-jackson/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"institution":[{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/"}]}}